March 04, 2015 3:47 AM ET


Company Overview of Tinea Pharmaceuticals, Inc.

Company Overview

Tinea Pharmaceuticals, Inc., a biopharmaceutical company, develops products for the treatment of onychomycosis or fungal infections of the toenail and nail bed. Its Luliconazole is a topical antifungal agent against a range of pathogens, including Trichophyton rubrum, Trichophyton mentagrophytes, and yeasts. The company was formerly known as Topica Pharmaceuticals, Inc. and changed its name to Tinea Pharmaceuticals, Inc. in September 2010. The company was founded in 2004 and is based in Palo Alto, California.

435 Tasso Street

Suite 325

Palo Alto, CA 94301-1555

United States

Founded in 2004



Key Executives for Tinea Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 53
Chief Financial Officer
Senior Vice President of Clinical Development and Operations
Senior Vice President of Regulatory & Quality
General Counsel and Secretary
Age: 64
Compensation as of Fiscal Year 2014.

Tinea Pharmaceuticals, Inc. Key Developments

Tinea Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013

Tinea Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

TOPICA Pharmaceuticals, Inc. Announces Results from Phase IIb/III Onychomycosis Study

TOPICA Pharmaceuticals, Inc. has announced interim safety and mycologic susceptibility results from the ongoing Phase IIb/III SOLUTION study evaluating 10% Luliconazole solution. With 334 patients enrolled in the clinical trial and approximately 50 patients having completed the study's protocol at week 52, Luliconazole Solution is very well tolerated topically and shows no signs of systemic side effects at this point in the trial. As part of the SOLUTION Study, clinical isolates were collected from 184 patients in the study and tested for mycologic susceptibility to TOPICA's 10% Luliconazole Solution. When clinical isolates (96.2% were T. rubrum) collected from patients participating in the SOLUTION Study were tested, luliconazole had a minimum inhibitory concentration (MIC90) of 0.0005 mcg/ml, confirming that the molecule is the most potent anti-fungal against the relevant fungi that cause onychomycosis. 'The blinded data show that when the active or vehicle control have been applied for up to 48 weeks in either of the two dosing regimens being evaluated by the clinical trial, they exhibit excellent local tolerability, a good clinical laboratory safety profile and an unremarkable safety profile based on the number of reported adverse events to date in the study.

Topica Pharmaceuticals Inc. Announces Completion of Enrollment in its Phase 2b/3 Onychomycosis Trial of 10% Luliconazole Solution

Topica Pharmaceuticals Inc. announced completion of enrollment in The "SOLUTION" Study, a 300-patient Phase 2b/3 clinical trial being conducted by the company. The clinical trial is a randomized, double-blind, vehicle-controlled, U.S. multicenter trial assessing the safety and efficacy of 10% Luliconazole Solution in two dosing regimens in patients with mild-to-moderate distal subungual onychomycosis of the toenails. TOPICA expects to report results from the trial in the second half of 2014. The completion of enrollment in this trial sets an exciting course for the product to potentially revolutionize the treatment of onychomycosis based on the potency of the molecule and a topical regimen that may be very safe, as well as convenient.

Similar Private Companies By Industry

Company Name Region
Pulmotect, Inc. United States
Choncept LLC United States
GenPhar, Incorporated United States
ImmunePath, Inc. United States
ValiGen Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tinea Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at